Buradasınız

Anasayfa » Content

Hemodiyaliz Hastalarında Rekombinan İnsan Eritropoetin-α ile İlişkili Hipertansiyonda Endotelinin ve Prostasiklinin Rolü

The Role of Endothelin and Prostacyclin on Recombinant Erythropoietin-α Induced Hypertension in Hemodialysis Patients

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2013
DOI: 
DOI 10.5262/tndt.2013.1001.13

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
OBJECTIVE: Recombinant human erythropoietin (r-HuEPO) was found to be associated with increased blood pressure in hemodialysis (HD) patients. Plasma endothelin-1(ET-1) was reported to be increased during treatment with r-huEPO in HD patients. Prostacyclin (PGI2) was found to be associated with the reduction in vascular resistance. We aimed to determine the role of ET-1 and PGI2 on r-huEPO-induced hypertension in HD patients. MA TERIAL and Metho ds: 43 HD patients (19 females, 24 males) were randomly assigned to groups. Group 1 (n=15) consisted of patients receiving r-HuEPO-α subcutaneously after each dialysis session for 6 to 42 months. Group 2 (n=15, control group) consisted of patients who did not receive any r-huEPO and group 3 (n=13) consisted of patients who received r-huEPO-α subcutaneously after each dialysis session for 12 weeks. Plasma ET-1,2 and 6-keto-PGF1-α were measured. Res ults : There were no differences in terms of ET-1,2 and 6-keto-PGF1-α, systolic and diastolic BP and hematocrit levels in group 1 and group 2 patients. However, in group 3 patients, hematocrit, plasma ET1,2 and 6-keto PGF1-α levels were significantly elevated after 12 weeks of rHuEPO treatment. ConclusIo n: We showed that ET-1.2 and 6-keto-PGF1-α levels were found to be significantly increased with 12 weeks of rHu-EPO therapy in HD patients.
Bookmark/Search this post with
Abstract (Original Language): 
AMA Ç: Hemodiyaliz (HD) hastalarında renal aneminin tedavisinde kullanılan rekombinan insan eritropoetin (rHuEPO) tedavisi artmış kan basıncı ile ilişkili bulunmuştur. Plazma endotelin 1 (ET1) konsantrasyonlarının hemodiyaliz hastalarında rHuEPO tedavisi esnasında yükseldiği tespit edilmiştir. Prostasiklin (PGI2) önemli bir vasodilatör madde olup vasküler dirençte azalma ile ilişkili bulunmuştur. Hemodiyaliz hastalarında rHuEPO ile ilişkili hipertansiyonda ET-1 ve PGI2 etkisini araştırmayı hedefledik. Gereç ve y önte mLER: 43 HD hastası (19 kadın, 24 erkek) rastgele olarak gruplara ayrıldı. Grup 1’deki hastalar (n=15), 6-42 ay boyunda her diyaliz seansı sonunda subkutan rHuEPO-α kullanan hastalar, grup 2’deki hastalar (n=15, kontrol grubu) hiç r-huEPO almayan hastalar, ve grup 3’teki hastalar (n=13) 12 hafta boyunca her diyaliz sonrasında subkutan rHuEPO-α kullanan hastalardı. Plazmada ET-1,2 ve 6-keto-PGF1-α ölçüldü. Bulgular: Grup 1 ve 2’deki hastalarda tedavi öncesinde ve sonrasında hematokrit, ET-1,2 ve 6-keto-PGF1-α düzeyleri ve sistolik ve diyastolik kan basınçları açısından bir fark saptanmadı. Bununla birlikte, grup 3 hastalarda 12 haftalık rHuEPO tedavisi sonrasında hematokrit, ET-1,2 ve 6-keto-PGF1-α düzeyleri anlamlı düzeyde artmış bulundu. Sonuç: Çalışmamızda, HD hastalarında 12 haftalık rHu-EPO tedavisi ile ET-1.2 ve 6-keto-PGF1- α’nın anlamlı olarak arttığını saptadık.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_22_pp_89-94.pdf
  • 1
89-94
  • Turkish

REFERENCES

References: 

1. Abraham PA, Macres MG: Blood pressure in hemodialysis patients
during amelioration of anemia with erythropoietin. J Am Soc
Nephrol 1991; 2 (4): 927-936
2. Mazzuchi N, Carbonell E, Fernandez-Cean J: Importance of blood
pressure control in hemodialysis patient survival. Kidney Int 2000;
58(5): 2147-2154
3. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes
PM: Effect of human erythropoietin derived from recombinant DNA
on the anaemia of patients maintained by chronic haemodialysis.
Lancet 1986; 2 (8517): 1175-1178
4. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson
JW: Correction of the anemia of end-stage renal disease with
recombinant human erythropoietin. Results of a combined phase I
and II clinical trial. N Engl J Med 1987; 316 (2): 73-78
5. Ottosson-Seeberger A, Ahlborg G, Hemsen A, Lundberg JM,
Alvestrand A: Hemodynamic effects of endothelin-1 and big
endothelin-1 in chronic hemodialysis patients. J Am Soc Nephrol
1999; 10(5): 1037-1044
6. Takahashi K, Totsune K, Imai Y, Sone M, Nozuki M, Murakami
O, Sekino H, Mouri T: Plasma concentrations of immunoreactiveendothelin
in patients with chronic renal failure treated with
recombinant human erythropoietin. Clin Sci (Lond) 1993; 84 (1):
47-50
7. Smith MC, Dunn MJ: The role of prostaglandins in human
hypertension. Am J Kidney Dis 1985; 5 (4): A32-39
8. Takayama K, Nagai T, Kinugasa E, Akizawa T, Koshikawa S:
Changes in endothelial vasoactive substances under recombinant
human erythropoietin therapy in hemodialysis patients. ASAIO
Trans 1991; 37 (3): 187-188
9. Uehara Y, Ishii M, Ikeda T, Atarashi K, Takeda T, Murao S: Plasma
levels of 6-keto-prostaglandin F1 alpha in normotensive subjects
and patients with essential hypertension. Prostaglandins Leukot
Med 1983; 10 (4): 455-464
10. Shimada N, Saka S, Sekizuka K, Tanaka A, Takahashi Y, Nakamura
T, Ebihara I, Koide H: Increased endothelin: Nitric oxide ratio
is associated with erythropoietin-induced hypertension in
hemodialysis patients. Ren Fail 2003; 25 (4): 569-578
11. Miyashita K, Tojo A, Kimura K, Goto A, Omata M, Nishiyama
K, Fujita T: Blood pressure response to erythropoietin injection in
hemodialysis and predialysis patients. Hypertens Res 2004; 27 (2):
79-84
12. Kirkpantur A, Kahraman S, Yilmaz R, Arici M, Altun B, Erdem Y,
Yasavul U, Turgan C: The effects of maintenance recombinant human
erythropoietin therapy on ambulatory blood pressure recordings:
Conventional, Doppler, and tissue Doppler echocardiographic
parameters. Artif Organs 2005; 29 (12): 965-972
13. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson
JW: Hypertension following erythropoietin therapy in anemic
hemodialysis patients. Am J Hypertens 1990; 3 (12 Pt 1): 947-955
14. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein
M: Recombinant human erythropoietin (rHuEPO) increases
endothelin-1 release by endothelial cells. Kidney Int 1993; 43 (5):
1010-1014
15. Mayer G, Horl WH: Cardiovascular effects of increasing hemoglobin
in chronic renal failure. Am J Nephrol 1996; 16 (4): 263-267
16. Lebel M, Kingma I, Grose JH, Langlois S: Hemodynamic and
hormonal changes during erythropoietin therapy in hemodialysis
patients. J Am Soc Nephrol 1998; 9 (1): 97-104
17. Sunder-Plassmann G, Horl WH: Effect of erythropoietin on
cardiovascular diseases. Am J Kidney Dis 2001; 38 (4 Suppl 1):
S20-25

Thank you for copying data from http://www.arastirmax.com